New combo attack on hard-to-treat lymphoma shows promise in early trial
NCT ID NCT06160843
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tests two drugs, pembrolizumab and olaparib, together in people with a rare type of blood cancer called peripheral T-cell lymphoma that has returned or not improved with prior therapy. The goal is to see if the combination can shrink or control the cancer. About 24 adults will receive the drugs in 3-week cycles until the cancer worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED PERIPHERAL T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Centre, Singapore
RECRUITINGSingapore, 168583, Singapore
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.